Valuation: VolitionRx Limited

Market Cap 11.83M 10.36M 9.56M 8.93M 16.81M 1.12B 17.19M 115M 44.42M 552M 44.42M 43.45M 1.92B P/E 2026 *
-0.64x
P/E 2027 * -1.02x
Enterprise Value 11.83M 10.36M 9.56M 8.93M 16.81M 1.12B 17.19M 115M 44.42M 552M 44.42M 43.45M 1.92B EV / Sales 2026 *
4.77x
EV / Sales 2027 * 2.06x
Free-Float
91.38%
Yield 2026 *
-
Yield 2027 * -
1 day+10.94%
1 week+5.97%
Current month-46.82%
1 month-46.82%
3 months-63.89%
6 months-70.42%
Current year-72.22%
1 week 1.17
Extreme 1.17
1.43
1 month 1.17
Extreme 1.17
2.9
Current year 1.17
Extreme 1.17
7.73
1 year 1.17
Extreme 1.17
16.39
3 years 1.17
Extreme 1.17
31
5 years 1.17
Extreme 1.17
82.8
10 years 1.17
Extreme 1.17
136.8
Manager TitleAgeSince
Chief Executive Officer 55 06/10/2011
Director of Finance/CFO 56 01/02/2021
Chief Tech/Sci/R&D Officer 49 01/04/2024
Director TitleAgeSince
Director/Board Member 55 06/10/2011
Director/Board Member 77 06/10/2011
Director/Board Member 64 09/10/2019
Date Insider Type Main position Quantity % Market Cap.
03-17
Concord International, Inc.
OtherCompany 0 0%
03-17Tax

Company Secretary

3,948 0.0029%
03-17Tax

Executive/Senior Manager

5,251 0.0039%
Change 5-day change 1-year change 3-year change Capi.($)
+10.94%+5.97%-91.52%-95.03% 10.66M
-0.50%+13.16%+119.83%+132.75% 4.83B
+2.10%+23.20%+81.51%+213.78% 3.35B
+3.58%-1.86%-26.99%-40.38% 1.96B
-0.94%+3.69%+149.11%-40.28% 1.9B
+1.60%+16.89%+52.26%+242.06% 1.49B
+2.73%+21.71%+158.70%-48.92% 917M
+8.75%+12.36%-7.73%+47.82% 842M
+1.59%-4.87%-37.37%-18.92% 466M
+17.16%-7.72%+16.56% - 435M
Average +4.70%+7.40%+41.44%+43.65% 1.62B
Weighted average by Cap. +1.88%+11.87%+79.51%+98.25%

Financials

2026 *2027 *
Net sales 2.48M 2.17M 2M 1.87M 3.52M 234M 3.6M 24.1M 9.3M 116M 9.3M 9.1M 401M 5.73M 5.02M 4.63M 4.33M 8.15M 542M 8.33M 55.77M 21.53M 267M 21.53M 21.06M 928M
Net income -22.2M -19.44M -17.95M -16.76M -31.55M -2.1B -32.27M -216M -83.38M -1.04B -83.38M -81.55M -3.6B -19.62M -17.18M -15.86M -14.81M -27.88M -1.85B -28.51M -191M -73.67M -915M -73.68M -72.06M -3.18B
Net Debt - -
Logo VolitionRx Limited
VolitionRx Limited is a multi-national company focused on advancing the science of epigenetics. The Company is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring. Through its subsidiaries, it is developing and commercializing blood tests to help diagnose and monitor a range of diseases, including cancers and diseases associated with NETosis, such as sepsis. Its key pillars are Nu.Q Vet, Nu.Q NETs, Nu.Q Discover, Nu.Q Cancer, and Capture-PCR. The Nu.Q Vet Cancer Test is commercially available as a cancer screening test in dogs. Nu.Q NETs is monitoring the immune system to save lives. Nu.Q Discover is a complete solution to profiling nucleosomes. Nu.Q Cancer monitoring disease progression, response to treatment and minimal residual disease. Capture-PCRTM is isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
Employees
67
Date Price Change Volume
29/06/26 $1.420 +10.94% 299,854
26/06/26 $1.280 -0.78% 122,605
25/06/26 $1.290 +4.88% 196,506
24/06/26 $1.230 +1.65% 163,196
23/06/26 $1.210 -9.70% 477,490
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.420USD
Average target price
16.97USD
Spread / Average Target
+1,094.79%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VNRX Stock